TY  - GEN
AU  - Dang,Chau
AU  - Lin,Nancy
AU  - Moy,Beverly
AU  - Come,Steven
AU  - Sugarman,Steven
AU  - Morris,Patrick
AU  - Abbruzzi,Alyson
AU  - Chen,Carol
AU  - Steingart,Richard
AU  - Patil,Sujata
AU  - Norton,Larry
AU  - Winer,Eric
AU  - Hudis,Clifford
TI  - Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea
SN  - 1527-7755
PY  - 2010///0706
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Cyclophosphamide
KW  - Diarrhea
KW  - chemically induced
KW  - Dose-Response Relationship, Drug
KW  - Doxorubicin
KW  - Feasibility Studies
KW  - Female
KW  - Filgrastim
KW  - Follow-Up Studies
KW  - Gene Amplification
KW  - Granulocyte Colony-Stimulating Factor
KW  - Humans
KW  - Immunoenzyme Techniques
KW  - In Situ Hybridization, Fluorescence
KW  - Lapatinib
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Neoplasm Staging
KW  - Paclitaxel
KW  - Pilot Projects
KW  - Polyethylene Glycols
KW  - Quinazolines
KW  - Receptor, ErbB-2
KW  - genetics
KW  - Recombinant Proteins
KW  - Survival Rate
KW  - Trastuzumab
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2009.26.5900
ER  -